(19) | |
| (11) | EP 3 540 054 A3 |
(12) | EUROPEAN PATENT APPLICATION |
(88) | Date of publication A3: | | 09.10.2019 Bulletin 2019/41 |
(43) | Date of publication A2: | | 18.09.2019 Bulletin 2019/38 |
(22) | Date of filing: 07.06.2007 |
| (51) | International Patent Classification (IPC): |
|
(84) | Designated Contracting States: | | AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
(30) | Priority: | 07.06.2006 US 81141906 P
|
(62) | Application number of the earlier application in accordance with Art. 76 EPC: | | 12152550.5 / 2489733 | | 07795835.3 / 2029742 |
(71) | Applicant: Genzyme Corporation | | Cambridge, MA 02142 (US) |
| (72) | Inventors: | | - DODGE, James
Shrewsbury, MA 01545 (US) - SHIHABUDDIN, Lamya
West Newton
MA 02465 (US) - O'RIORDAN, Catherine R.
Waban, MA 02468 (US)
|
(74) | Representative: Rai, Monika et al | | Mathys & Squire LLP
The Shard
32 London Bridge Street London SE1 9SG London SE1 9SG (GB) |
|
| |
(54) | GENE THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS AND OTHER SPINAL CORD DISORDERS |
(57) This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject's spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the subject's brain.